Keith Stewart

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

Joseph Mıkhael, David Dingli, Vivek Roy et al. · Mayo Clinic Proceedings · 2013 · 485 citations

Hematological Malignancy, Oncology, Hematology +7

Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis

Karla Kerlikowske, Annette M. Molinaro, Marie-Pier Gauthier et al. · JNCI Journal of the National Cancer Institute · 2010 · 346 citations · Full text

MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD

Clifford R. Jack, M Słomkowski, S. Gracon et al. · Neurology · 2003 · 294 citations

Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma

Hong Chang, Young Trieu, Xiaoying Qi et al. · Leukemia Research · 2006 · 89 citations

Hematological Malignancy, Medicine, Hematology +8

Combined venetoclax and alvocidib in acute myeloid leukemia

James M. Bogenberger, Clifford J. Whatcott, Nanna Hansen et al. · Oncotarget · 2017 · 88 citations · Full text